The Patent Finder
US

Use of NK-1 Receptor Antagonist Serlopitant in Pruritus

US 9,737,507 Lapsed on the fee record
OverviewFamilyAssignmentsSources & methods

Lapsed Aug 22, 2025 on the fee record · Medium confidence

Why Medium: A terminal disclaimer is on file (approved) with no resolved reference, so the term may end earlier.

Second maintenance fee unpaid; grace period ended.

Filed Sep 19, 2016 as application 15/269,792 · Granted Aug 22, 2017
USPTO first gave this application the number US 9,707,208 and withdrew it before it issued. That number now leads here.
Base term, 20 years from filing
Today
Lapsed Aug 22, 2025
2013 2033
Clock starts
Jun 24, 2013
No longer in force
Aug 22, 2025
Granted
Aug 22, 2017
Term would have run to
Jun 24, 2033
base term after the term ends fee events Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
Unresolved
Terminal disclaimer
On file, reference document not resolved, so the date above is an upper bound. We do not guess the cap.
1 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
15
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.

Its term would have run to Jun 24, 2033: its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is on file with no resolved reference, so no cap is applied and none is guessed. Confidence: Medium. from the record

How we calculated this date

One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
StepInputDate after this stepConfidence
Base term, 20 years from filingClock starts Jun 24, 2013, when application 13/925,509, the earliest non-provisional in its chain, was filed (this one was filed Sep 19, 2016)Jun 24, 2033High confidence
Continuity chainEvery parent in the chain resolvedno changeHigh confidence
Patent term adjustmentNone on fileno changeHigh confidence
Terminal disclaimer capDisclaimer on file (approved), reference document not resolvedno cap applied, and none guessedMedium confidence
Patent term extensionNone on fileno changeHigh confidence
Fee events1 of 3 maintenance fees paidlapsed Aug 22, 2025High confidence
Computed term endThe steps above, in orderAug 22, 2025Medium confidence

This family

US 8,906,951In force
Jun 2033
Jun 2033
US 9,198,898Lapsed on the fee record
Dec 2023
Dec 2023
Application PCT/US2014/043811PCT application
no patent term
no patent term
US 9,381,188Lapsed on the fee record
Jul 2024
Jul 2024
US 9,486,439Lapsed on the fee record
Nov 2024
Nov 2024
US 9,474,741Lapsed on the fee record
Oct 2024
Oct 2024
US 9,737,507this patent
Aug 2025
Aug 2025
US 9,737,508Lapsed on the fee record
Aug 2025
Aug 2025
8 of 15 applications in this family shown, earliest filings first. Every application listed has its file history here. The family may have others.

Assignments

Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
RecordedAssignorAssigneeConveyance
May 5, 2017
Reel 42258, frame 517
Zhang, Xiaoming; Schnipper, Edward F.; Perlman, Andrew J.; Larrick, James W.Tigercat Pharma, Inc.Assignment of Assignor's Interest
May 5, 2017
Reel 42418, frame 481
Tigercat Pharma, Inc.Menlo Therapeutics Inc.Change of Name
Mar 9, 2020
Reel 52130, frame 980
Menlo Therapeutics Inc.Perceptive Credit Holdings II, LPPatent Security Agreement
Dec 1, 2020
Reel 54558, frame 437
Menlo Therapeutics Inc.Vyne Therapeutics Inc.Change of Name
Sep 20, 2021
Reel 57531, frame 986
Perceptive Credit Holdings II, LPVyne Therapeutics Inc. (F/K/A Menlo Therapeutics Inc. and Successor-in-Interest to Vyne Pharmaceuticals Ltd., F/K/A Foamix Pharmaceuticals Ltd.)Release of Security Interest

Sources

Google Patents · The patent document at USPTO · Assignment records at USPTO

USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup

Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited